Email This Release
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire